全文获取类型
收费全文 | 663篇 |
免费 | 53篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 12篇 |
妇产科学 | 9篇 |
基础医学 | 97篇 |
口腔科学 | 1篇 |
临床医学 | 97篇 |
内科学 | 179篇 |
皮肤病学 | 6篇 |
神经病学 | 36篇 |
特种医学 | 27篇 |
外科学 | 96篇 |
综合类 | 4篇 |
预防医学 | 71篇 |
眼科学 | 5篇 |
药学 | 44篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 14篇 |
2020年 | 17篇 |
2019年 | 13篇 |
2018年 | 21篇 |
2017年 | 12篇 |
2016年 | 18篇 |
2015年 | 21篇 |
2014年 | 16篇 |
2013年 | 29篇 |
2012年 | 40篇 |
2011年 | 42篇 |
2010年 | 14篇 |
2009年 | 18篇 |
2008年 | 36篇 |
2007年 | 36篇 |
2006年 | 34篇 |
2005年 | 34篇 |
2004年 | 31篇 |
2003年 | 27篇 |
2002年 | 39篇 |
2001年 | 26篇 |
2000年 | 19篇 |
1999年 | 17篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 13篇 |
1995年 | 6篇 |
1994年 | 6篇 |
1993年 | 3篇 |
1992年 | 8篇 |
1991年 | 5篇 |
1990年 | 8篇 |
1989年 | 6篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 9篇 |
1977年 | 2篇 |
1975年 | 5篇 |
1967年 | 1篇 |
1965年 | 1篇 |
1938年 | 1篇 |
1935年 | 1篇 |
1933年 | 1篇 |
排序方式: 共有717条查询结果,搜索用时 62 毫秒
31.
The combination of high-dose busulfan (16 mg/kg) and 200 mg/kg cyclophosphamide is gaining increasing significance as a preparative regimen prior to autologous, syngeneic, or allogeneic marrow transplantation. A new regimen of high-dose busulfan in conjunction with a reduced dose of 120 mg/kg cyclophosphamide has recently been described as a preparative regimen prior to allogeneic transplantation. To determine the drug-related nonhematologic toxic effects of this new regimen without confounding factors associated with allogeneic transplantation, we conducted a pilot study using this new regimen in 20 patients with acute myeloid leukemia (AML) in first remission prior to autologous unpurged marrow transplantation. All patients experienced transient non-life-threatening acute drug-related toxicity with skin reactions in 20 (100%), nausea and vomiting in 20 (100%), oral mucositis in 18 (90%), hepatic functional impairment in 17 (85%), hemorrhagic cystitis in three (15%), and generalized seizures in two (10%) of these patients, respectively. Two procedural, fatal complications resulted from infectious causes that were not directly related to the speed of hematopoietic reconstitution or the toxicity of the preparative regimen. The 3-year event-free survival estimate (55% +/- 11%) and probability of leukemic recurrence (38% +/- 11%) attained with this new regimen in recipients of autografts in first remission of AML are promising and challenge comparisons with preparative regimens employing combinations of cytotoxic agents or total body irradiation (TBI). 相似文献
32.
Gisela G. Slaats Joshua C. Saldivar Julien Bacal Michelle K. Zeman Andrew C. Kile Ann Marie Hynes Shalabh Srivastava Jekaterina Nazmutdinova Krista den Ouden Miriam S. Zagers Veronica Foletto Marianne C. Verhaar Colin Miles John A. Sayer Karlene A. Cimprich Rachel H. Giles 《The Journal of clinical investigation》2015,125(9):3657-3666
Juvenile ciliopathy syndromes that are associated with renal cysts and premature renal failure are commonly the result of mutations in the gene encoding centrosomal protein CEP290. In addition to centrosomes and the transition zone at the base of the primary cilium, CEP290 also localizes to the nucleus; however, the nuclear function of CEP290 is unknown. Here, we demonstrate that reduction of cellular CEP290 in primary human and mouse kidney cells as well as in zebrafish embryos leads to enhanced DNA damage signaling and accumulation of DNA breaks ex vivo and in vivo. Compared with those from WT mice, primary kidney cells from Cep290-deficient mice exhibited supernumerary centrioles, decreased replication fork velocity, fork asymmetry, and increased levels of cyclin-dependent kinases (CDKs). Treatment of Cep290-deficient cells with CDK inhibitors rescued DNA damage and centriole number. Moreover, the loss of primary cilia that results from CEP290 dysfunction was rescued in 3D cell culture spheroids of primary murine kidney cells after exposure to CDK inhibitors. Together, our results provide a link between CEP290 and DNA replication stress and suggest CDK inhibition as a potential treatment strategy for a wide range of ciliopathy syndromes. 相似文献
33.
34.
35.
36.
37.
C. Cooper R. Fielding M. Visser L. J. van Loon Y. Rolland E. Orwoll K. Reid S. Boonen W. Dere S. Epstein B. Mitlak Y. Tsouderos A. A. Sayer R. Rizzoli J. Y. Reginster J. A. Kanis 《Calcified tissue international》2013,93(3):201-210
This review provides a framework for the development of an operational definition of sarcopenia and of the potential end points that might be adopted in clinical trials among older adults. While the clinical relevance of sarcopenia is widely recognized, there is currently no universally accepted definition of the disorder. The development of interventions to alter the natural history of sarcopenia also requires consensus on the most appropriate end points for determining outcomes of clinical importance which might be utilized in intervention studies. We review current approaches to the definition of sarcopenia and the methods used for the assessment of various aspects of physical function in older people. The potential end points of muscle mass, muscle strength, muscle power, and muscle fatigue, as well as the relationships between them, are explored with reference to the availability and practicality of the available methods for measuring these end points in clinical trials. Based on current evidence, none of the four potential outcomes in question is sufficiently comprehensive to recommend as a uniform single outcome in randomized clinical trials. We propose that sarcopenia may be optimally defined (for the purposes of clinical trial inclusion criteria as well as epidemiological studies) using a combination of measures of muscle mass and physical performance. The choice of outcome measures for clinical trials in sarcopenia is more difficult; co-primary outcomes, tailored to the specific intervention in question, may be the best way forward in this difficult but clinically important area. 相似文献
38.
39.
Karem. H. Alzoubi Omar. F. Khabour Noor H. Tashtoush Sayer I. Al‐azzam Nizar M. Mhaidat 《Hippocampus》2013,23(9):812-819
In this study, we examined the ability of Pentoxifylline (PTX) to prevent sleep deprivation induced memory impairment probably through decreasing oxidative stress. Sleep deprivation was chronically induced 8 h/day for 6 weeks in rats using modified multiple platform model. Concurrently, PTX (100 mg/kg) was administered to animals on daily basis. After 6 weeks of treatment, behavioral studies were conducted to test the spatial learning and memory using the Radial Arm Water Maze. Additionally, the hippocampus was dissected; and levels/activities of antioxidant defense biomarkers glutathione reduced (GSH), glutathione oxidized (GSSG), GSH/GSSG ratio, glutathione peroxidase (GPx), catalase, and superoxide dismutase (SOD), were assessed. The results show that chronic sleep deprivation impaired short‐ and long‐term memories, which was prevented by chronic treatment with PTX. Additionally, PTX normalized sleep deprivation‐induced reduction in the hippocampus GSH/GSSG ratio (P < 0.05), and activities of GPx, catalase, and SOD (P < 0.05). In conclusion, chronic sleep deprivation induces memory impairment, and treatment with PTX prevented this impairment probably through normalizing antioxidant mechanisms in the hippocampus. © 2013 Wiley Periodicals, Inc. 相似文献